Plain-English translation of NCT05852704 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called dapagliflozin can help prevent serious complications after heart bypass surgery. Specifically, researchers want to know if taking this medication daily — starting before surgery and continuing through hospital discharge — can reduce the risk of irregular heart rhythms and kidney damage that sometimes occur after bypass surgery.
After heart bypass surgery, some patients develop dangerous irregular heartbeats or kidney problems during their hospital stay. Doctors hope that starting this medication before surgery might protect the heart and kidneys during this stressful time.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll be randomly assigned to take either the study medication or a placebo (inactive pill) once daily for at least one week before your scheduled bypass surgery, and you'll continue taking it until you leave the hospital after surgery. You'll receive a safety phone call one week after discharge, and researchers will check on your health at 30 days and 12 months using medical records. The study takes place at centers in Sweden, Denmark, and the Czech Republic.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Czechia
Denmark
Sweden